Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorBORDET, Constance
dc.contributor.authorGARCIA, Philippe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
IDREF: 221043470
dc.contributor.authorTOUAFCHIA, Anthony
dc.contributor.authorGALINIER, Michel
dc.contributor.authorSOMMET, Agnes
dc.contributor.authorMONTASTRUC, Francois
dc.date.accessioned2023-02-15T09:04:02Z
dc.date.available2023-02-15T09:04:02Z
dc.date.issued2022-12-14
dc.identifier.issn1432-2072 (Electronic) 0033-3158 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171951
dc.description.abstractEnRATIONALE: While meta-analyses of clinical trials found that lurasidone and partial dopamine agonists (brexpiprazole and aripiprazole) were the antipsychotics less likely to cause QTc prolongation, and sertindole, amisulpride, and ziprasidone were the most frequently associated with this adverse drug reaction; no real-world studies have investigated this risk between the different antipsychotics. OBJECTIVES AND METHODS: Using data recorded from 1967 to 2019 in VigiBase®, the World Health Organization's Global Individual Case Safety Reports database, we performed disproportionality analysis to investigate the risk of reporting QT prolongation between 20 antipsychotics. RESULTS: Sertindole had the highest risk of reporting QT prolongation, followed by ziprasidone and amisulpride. Lurasidone was associated with the lowest risk. First-generation antipsychotics were associated with a greater QT prolongation reporting risk (ROR, 1.21; 95%CI, 1.10-1.33) than second-generation antipsychotics. A positive correlation was found between the risk of reporting QT prolongation and affinity for hERG channel (R(2) = 0.14, slope = Pearson coefficient = 0.41, p value = 0.1945). CONCLUSIONS: This large study in a real-world setting suggests that sertindole and ziprasidone were the antipsychotics drugs associated with the highest risk of QT prolongation reporting. Our results suggest that lurasidone is less associated with QT interval prolongation reports. Our study also suggests that antipsychotics with the higher hERG affinity are more associated with to QT prolongations reports.
dc.language.isoENen_US
dc.subject.enAntipsychotics
dc.subject.enQT prolongation
dc.subject.enPharmacovigilance
dc.subject.enhERG
dc.subject.enLurasidone
dc.title.enAntipsychotics and risk of QT prolongation: a pharmacovigilance study
dc.title.alternativePsychopharmacology (Berl)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00213-022-06293-4en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36515735en_US
bordeaux.journalPsychopharmacologyen_US
bordeaux.page199-202en_US
bordeaux.volume240en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03989901
hal.version1
hal.date.transferred2023-02-15T09:04:09Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Psychopharmacology&rft.date=2022-12-14&rft.volume=240&rft.spage=199-202&rft.epage=199-202&rft.eissn=1432-2072%20(Electronic)%200033-3158%20(Linking)&rft.issn=1432-2072%20(Electronic)%200033-3158%20(Linking)&rft.au=BORDET,%20Constance&GARCIA,%20Philippe&SALVO,%20Francesco&TOUAFCHIA,%20Anthony&GALINIER,%20Michel&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée